News

A Guide to Nursing Discharge of Patients Receiving CAR T-Cell Therapy

Ensuring that oncology staff is adequately trained on CAR T-cell therapy and the potential adverse effects is of the utmost importance. With multiple recent FDA approvals for the use of chimeric antigen receptor (CAR) T-cell therapy, including the treatment of acute lymphocytic leukemia, diffuse large B-cell lymphoma, as well as a multitude of clinical trials, creating standards for nursing care is essential.

READ FULL ARTICLE ON ONCNURSINGNEWS.COM